Ari Cohen

Paris

Co-Founder and CEO at Demotivateur

Featured in: Favicon

Articles

Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis - Nature Metabolism

Sep 26, 2024 | nature.com | Sandeep Das |Alexandra C Finney |Sumit Anand |Alia Ghrayeb |Kelley G. Núñez |Fabio Arias | +23 more

AbstractThe incidence of metabolic dysfunction-associated steatohepatitis (MASH) is on the rise, and with limited pharmacological therapy available, identification of new metabolic targets is urgently needed. Oxalate is a terminal metabolite produced from glyoxylate by hepatic lactate dehydrogenase (LDHA). The liver-specific alanine-glyoxylate aminotransferase (AGXT) detoxifies glyoxylate, preventing oxalate accumulation.
Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis - Nature Metabolism

Sep 26, 2024 | nature.com | Sandeep Das |Alexandra C Finney |Sumit Anand |Alia Ghrayeb |Kelley G. Núñez |Fabio Arias | +23 more

AbstractThe incidence of metabolic dysfunction-associated steatohepatitis (MASH) is on the rise, and with limited pharmacological therapy available, identification of new metabolic targets is urgently needed. Oxalate is a terminal metabolite produced from glyoxylate by hepatic lactate dehydrogenase (LDHA). The liver-specific alanine-glyoxylate aminotransferase (AGXT) detoxifies glyoxylate, preventing oxalate accumulation.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.